BioEngine Unveils UltraFeed: Revolutionizing Monoclonal Antibody Production

Shanghai BioEngine Sci-tech Co., Ltd. has launched UltraFeed, a cutting-edge fed-batch supplement that significantly boosts CHO cell productivity in monoclonal antibody and protein manufacturing. With an average titer increase of 25% and peak gains of 48%, UltraFeed offers enhanced process robustness and product quality across diverse cell lines.

Shanghai BioEngine Sci-tech Co., Ltd. has introduced UltraFeed, a state-of-the-art fed-batch supplement aimed at enhancing CHO cell productivity in the production of monoclonal antibodies and recombinant proteins.

The launch of UltraFeed addresses critical challenges faced in volumetric productivity and process robustness, offering an average titer increase of 25% compared to other feed media under similar basal conditions. In certain projects, the increase has reached an impressive 48%.

UltraFeed, which is compatible with any commercial basal medium, demonstrates synergistic effects when used with BioEngine's Eden CHO CD platform. This combination enhances cell density, lactate consumption efficiency, and overall product quality, making UltraFeed a significant advancement in cell culture technology.